Medical Patent Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Patent Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
HIV/AIDS
Rigel Ubiquitin Ligase Program Identifies Molecules With Anti-HIV Activity
April 11th, 2007
Rigel announced that Yonchu Jenkins, Ph.D., Associate Director of Virology, will be presenting on the company's efforts to develop a small molecule therapeutic to treat patients with the Human Immunodeficiency Virus (HIV) infection at the Keystone Symposium in British Columbia on March 27th and 29th. Dr. Jenkins will present both a poster and an oral presentation entitled, the Identification of Novel Antiretroviral Compounds by Targeting HIV Vif Function. Dr. Jenkins and her colleagues at Rigel are investigating ways to inhibit Vif, a specific viral protein produced by HIV that is essential for its replication. Inside HIV-infected cells, the invading protein, Vif,...
Source: Medical Patent Law Weekly (2007-04-11)
|
